Our analyses of CD11b/LIF transgenic mdx mice showed that the transgene reduces muscle inflammation and fibrosis, thereby validating the transgene as a therapeutic molecule for muscular dystrophy. This evidence concerns the gene LIF and muscular dystrophy.